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ABSTRACT
Background    This study examined the treatment sat-
isfaction of type 1 diabetic patients undergoing continu-
ous subcutaneous insulin infusion (CSII) therapy, and 
patients’ thoughts regarding CSII. 
Methods    We provided a self-administered question-
naire survey over the internet. Participants were 106 
individuals with type-one diabetes aged 20 years or 
older, undergoing CSII. The survey examined patients’ 
treatment satisfaction, and their thoughts regarding CSII. 
Descriptive statistics were calculated. We compared 
relationships between treatment satisfaction and other 
variables using the Kruskal-Wallis rank sum test, and 
performed content analysis on participants’ thoughts re-
garding CSII.
Results    Regarding treatment satisfaction, the re-
sponse, “neither of them” was the most frequent. Com-
paring relationships between treatment satisfaction and 
other variables, significant differences were found for 
the variables “age,” “presence of dissatisfaction regard-
ing doctors’ response,” and “presence of a significant 
medical expense burden.” Participants’ thoughts regard-
ing CSII were classified into 10 categories. 
Conclusion    Participants expressed positive evalu-
ations, such as that their blood sugar control had im-
proved due to CSII, and that they perceived improve-
ment in their health. Participants also expressed negative 
evaluations, however, such as that medical expenses 
resulting from CSII were high, and that these expenses 
may cause distress and future economic insecurity. In 
future, patients may benefit from nursing support that al-
lows patients to confidently continue with CSII.
Key words    continuous subcutaneous insulin infusion; 
treatment satisfaction; type 1 diabetes
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Type 1 diabetes is a disease in which pancreatic beta-
cells are destroyed, causing low insulin secretion that 
leads to a state of absolute insulin deficiency. Approxi-
mately 8,000 people currently suffer from type 1 diabe-
tes in Japan as reported by the Ministry of Health, La-
bour and Welfare. It often develops during childhood or 
adolescence. Patients require lifetime insulin treatment 
to survive.
 Blood sugar control in types 1 and 2 diabetes pa-
tients is influenced by meal content, volume, and timing, 
as well as degree of physical activity and physical con-
dition. Patients must therefore adjust their insulin dos-
age and the timing of insulin injections to match these 
variables.1 However, this is a major challenge and many 
patients are unable to successfully control their blood 
sugar levels. A growing number of patients are therefore 
choosing to undergo continuous subcutaneous insulin 
infusion (CSII) therapy to make their treatment regi-
mens match their lifestyle more closely. CSII therapy is 
a method of continuously pumping insulin via a subcuta-
neous infusion route into the patient’s abdominal wall. A 
meta-analysis comparing multiple daily injection (MDI) 
therapy with CSII therapy has shown that CSII therapy 
produces better blood sugar and HbA1c levels than MDI 
therapy does and enables insulin dosages to be reduced. 
The usefulness of CSII therapy is also being seen in 
insulin-dependent diabetes patients whose insulin secre-
tion capabilities have been significantly impaired and in 
pregnant women suffering diabetic complications with 
wide fluctuations in blood sugar levels.2, 3
 Although CSII therapy is widely known in the U.S. 
and other countries as one option for diabetic insulin 
therapy, it remains little known in Japan and is not wide-
ly used. Because of this, very few studies have thus far 
been published and the opinions of patients undergoing 
CSII therapy and their degree of satisfaction with it are 
not yet known.
 We therefore decided to conduct a study targeting 
type 1 diabetes patients undergoing CSII therapy with 
the aim of investigating their opinions on this treatment 
and their degree of satisfaction with it. The objective was 
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to make the findings of this study useful for providing 
nursing assistance to type 1 diabetes patients who are on 
CSII therapy.
SUBJECTS AND METHODS
Participants and data collection
With the cooperation of Eli Lilly Japan (Kobe, Japan), 
we used type 1 diabetes patients on CSII therapy, aged 
over 20, and registered with the Diabetes Net’s email 
magazine as the study participants. We asked the indi-
viduals to answer a questionnaire survey via the Inter-
net. We displayed the questionnaire sheets and answer 
columns on the web and asked the individuals to send 
their answers to us. A total of 106 patients were used as 
the study participants.
 The questionnaire consisted of eleven items alto-
gether, including six items on basic attributes, one on the 
participants’ degree of satisfaction with CSII therapy, 
and five on their opinions about diabetes treatment: i) 
I have never been dissatisfied with the way the doctor 
dealt with me; ii) My current work is not affected by my 
diabetes; iii) I am mentally stable; iv) I do not mind if 
the treatment is complicated, as long as my diabetes im-
proves and v) Payment for medical treatments imposes a 
heavy financial burden. It also included an unstructured 
section asking the participants’ opinions on CSII thera-
py. Data were collected from 106 participants between 
March and April 2013.
Data analysis
Simple compilations were made for “basic attributes,” 
“degree of satisfaction with CSII therapy,” and “views 
on diabetes treatment.” We used the Kruskal-Wallis 
rank sum test to compare the relationships between 
“basic attributes” and “degree of satisfaction with CSII 
therapy” and between “views on diabetes treatment” 
and “degree of satisfaction with CSII therapy.” Analysis 
was completed using SPSS Statistics for Windows (IBM, 
Armonk, NY) with a significance level of 5%. We used 
qualitative software to perform content analysis (as de-
fined by Bernard Berelson) on the participants’ opinions 
about CSII therapy (unstructured section).
Ethical considerations
The participants were told, via the Internet, that infor-
mation obtained in the course of the study would not be 
used for purposes other than research, that the survey 
was being completed anonymously so individuals would 
not be identified, that their study participation was based 
on their own free will, and that they would not suffer 
any disadvantages even if they refused to provide an-
swers. The subjects were regarded as having given us 
their consent to participate in the study once they had 
answered the questionnaire and returned it to us. Eli 
Lilly Japan obtained approval from the responders. 
RESULTS
The study participants’ basic attributes
Table 1 shows the study participants’ basic attributes.
Table 1. The study participants’ basic attributes
Item n (%)
Gender
Male  23 (21.7)
Female  83 (78.3)
Age groups
(years)
< 30  14 (13.2)
30–39  39 (36.8)
40–49  27 (25.5)
50–59  19 (17.9)
60–69  5 (6.6)
Occupation
Employed  51 (48.1)
Unemployed  55 (51.9)
Marital status
Single  62 (58.5)
Married  44 (41.5)
Duration of diabetes
(years)
< 5  26 (24.5)
5–10  13 (12.3)
11–20  29 (27.4)
> 20  38 (35.8)
Monthly amount of the 
medical expenses
(yen)
< 5000  4 (3.8)
5000–10000  1 (0.9)
10000–15000  10 (9.4)
15000–20000  48 (45.3)
> 20000  43 (40.6)
Degree of satisfaction with CSII therapy
Concerning “degree of satisfaction with CSII therapy,” 
25 participants (23.6%) were “satisfied,” 18 (17.0%) were 
“dissatisfied,” and 63 (59.4%) were “neither satisfied nor 
dissatisfied.” The most frequently-cited answer was “nei-
ther satisfied nor dissatisfied.”
Views on diabetes treatment 
Almost two-thirds (n = 74 or 69.8%) of participants af-
firmed that they “did not mind if the treatment is com-
plicated, as long as my diabetes improves.” Sixty-three 
(59.4%) affirmed their “current work is not affected 
by my diabetes” and sixty (56.6%) affirmed their own 
mental stability. Many patients answered “yes” for these 
three items. On the other hand, a similar percentage (n = 
61 or 59.4%) indicated they “had been dissatisfied with 
the way the doctor dealt with me.” Slightly more than 
half (n = 57 or 53.8%) denied that payment for medical 
treatment was a burden. Many patients answered “no” 
to these two items.
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Comparison of the relationship between the par-
ticipants’ basic attributes and their degree of sat-
isfaction with CSII therapy
A significant difference in age was seen in comparing 
the relationship between the participants’ basic attri-
butes and their degree of satisfaction with CSII therapy. 
No significant differences were seen by gender, marital 
status, occupation, treatment history, or the amount of 
monthly medical payments. Many of those who an-
swered that they were “satisfied” had a long treatment 
history (Table 2). 
Table 2. Comparison of the relationship between the participants’ basic attributes and their degree of  
satisfaction with CSII therapy








Male  6 (5.7)  3 (2.8)  14 (13.2)  23 (217)
ns
Female  19 (17.2)  15 (14.2)  49 (46.2)  83 (78.3)
Age groups
(years)
< 30  4 (3.8)  3 (2.8)  7 (6.6)  14 (13.2) ✽
30–39  11 (10.4)  9 (8.5)  19 (17.9)  39 (36.8) ✽
40–49  8 (7.5)  4 (3.8)  15 (14.1)  27 (25.5) ✽
50–59  2 (1.9)  2 (1.9)  15 (14.1)  19 (17.2) ✽
60–69  0 (0)  0 (0)  7 (6.6)  7 (7.3) ✽
Occupation
Employed  13 (12.3)  6 (5.7)  25 (23.6)  44 (41.5)
ns
Unemployed  12 (11.3)  12 (11.3)  38 (35.9)  62 (58.5)
Marital status
Single  13 (12.3)  10 (9.4)  32 (30.2)  55 (51.9)
ns
Married  12 (11.3)  8 (7.5)  31 (29.3)  51 (48.1)
Duration of diabetes
(years)
< 5  5 (4.7)  4 (3.8)  17 (16.0)  26 (24.5)
ns
5–10  4 (3.8)  3 (2.8)  6 (5.7)  13 (12.3)
11–20  4 (3.8)  8 (7.5)  17 (16.0)  29 (27.4)
> 20  12 (11.3)  3 (2.8)  23 (21.7)  38 (35.9)
Monthly amount of 
the medical expenses
(yen)
< 5000  1 (0.9)  1 (0.9)  2 (1.9)  4 (3.8)
ns
5000–10000  1 (0.9)  0 (0)  0 (0)  1 (0.9)
10000–15000  3 (2.8)  0 (0)  7 (6.6)  10 (9.49
15000–20000  11 (10.4)  10 (9.4)  27 (25.5)  48 (45.3)
> 20000  9 (8.5)  7 (6.6)  27 (25.5)  43 (40.6)
*P < 0.05. CSII, continuous subcutaneous insulin infusion; ns, not significant.
Table 3. Comparison of the relationship between the participants’ degree of satisfaction with CSII treatment and 
their views on diabetes treatment 







1. I have never been dissatisfied with 
the way the doctor dealt with me
Yes  10 (13.5)  5 (6.8)  16 (21.6)  31 (29.2)
ns
No  15 (20.3)  13 (17.5)  46 (62.2)  74 (69.8)
2. My current work is not affected by 
my diabetes
Yes  9 (12.2)  9 (12.2)  20 (27.0)  38 (35.8)
ns
No  16 (21.6)  8 (10.8)  39 (52.7)  63 (59.4)
3. I am mentally stable
Yes  14 (18.9)  8 (10.8)  38 (51.4)  60 (56.6)
ns
No  1 (1.4)  9 (12.2)  24 (32.4)  34 (32.1)
4. I do not mind if the treatment is 
complicated, as long as my diabetes 
improves
Yes  17 (23.0)  15 (20.3)  29 (39.2)  61 (57.5)
✽
No  8 (10.8)  2 (2.7)  33 (44.6)  43 (40.6)
5. Payment for medical treatments  
imposes a heavy financial burden
Yes  16 (21.6)  10 (13.5)  23 (31.1)  49 (46.2)
✽
No  9 (12.2)  8 (10.8)  40 (54.1)  57 (53.8)
*P < 0.05. CSII, continuous subcutaneous insulin infusion; ns, not significant.
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Comparison of the relationship between the partic-
ipants’ degree of satisfaction with CSII treatment 
and their views on diabetes treatment
In comparing the relationship between the participants’ 
views on diabetes treatment and their degree of satisfac-
tion with CSII therapy, we found a significant difference 
for the items, “I do not mind if the treatment is com-
plicated, as long as my diabetes improves;” and “pay-
ment for medical treatments imposes a heavy financial 
burden.” No significant differences were seen in the 
following items: “I have never been dissatisfied with the 
way the doctor dealt with me”, “my current work is not 
affected by my diabetes;” and “I am mentally stable” 
(Table 3).
The participants’ thoughts on CSII therapy: Un-
structured opinions 
Participants’ thoughts on CSII therapy were divided into 
the following ten categories: i) gratitude for CSII thera-
py; ii) hopes for CSII therapy; iii) drawing a distinction 
between type 2 and type 1 diabetes; iv) CSII therapy’s 
unique burden on the body; v) the burden of making 
monthly hospital visits; vi) a feeling of distrust in health-
care providers; vii) a sense of financial difficulty due to 
medical payments; viii) a sense of distrust in high medi-
cal fees; ix) financial anxieties about the future and x) 
hopes for medical advancements (Table 4).
Table 4. The participants’thoughts on CSII therapy: 
Unstructured opinions
Categories Number of data (%)
Gratitude for CSII therapy  8 (6.2)
Hopes for CSII therapy  2 (1.5)
Drawing a distinction between type 2 and 
type 1 diabetes  5 (4.0)
CSII therapy’s unique burden on the body  2 (1.5)
The burden of making monthly hospital 
visits  12 (9.2)
A feeling of distrust in healthcare providers  8 (6.2)
A sense of financial difficulty due to medi-
cal payments  36 (27.7)
A sense of distrust in high medical fees  18 (13.8)
Financial anxieties about the future  11 (8.5)
Hopes for medical advancements  28 (21.5)
CSII, continuous subcutaneous insulin infusion.
DISCUSSION
Relationship between basic attributes and degree 
of satisfaction with CSII therapy 
In terms of the degree of satisfaction with CSII therapy, 
approximately 20% of the patients answered that they 
were satisfied and approximately 10% answered that 
they were dissatisfied. However, the largest number of 
patients—approximately 60%—answered that they were 
neither satisfied nor dissatisfied. The more favorable the 
blood sugar control of type 1 diabetes patients is, the 
higher their degree of satisfaction with treatment tends 
to be.4 With CSII therapy, moreover, a certain amount 
of time is needed to set the basal levels and to master the 
technique of handling the insulin pump and peripheral 
equipment; it takes time to prepare all of the conditions 
necessary for improving blood sugar control. Even if 
patients switch to CSII therapy, not everyone sees their 
blood sugar control improve.5 Therefore, many of our 
study’s targets were assumed to have answered “neither 
satisfied nor dissatisfied” since they felt that, even if they 
switched to CSII therapy, their mastery of the techniques 
might be insufficient or their blood sugar control might 
not improve. On the other hand, insulin is their lifeline 
and they cannot revert to worsening health. As a result, 
they could not select either “satisfied” or “dissatisfied.”
 In a comparison of the relationship between the par-
ticipants’ basic attributes and their degree of satisfaction 
with CSII therapy, a significant difference was seen in 
terms of age. Most participants were in their 30s to 40s. 
In terms of treatment history, many had been in treat-
ment for 20 or more years, followed by 10–20 years, 
so the age of onset is assumed to have been when the 
participants were relatively young. It is reported that, 
when patients who have undergone MDI therapy for 
many years switch to CSII therapy, their burden both at 
work and in family living is reduced. On the other hand, 
however, CSII therapy has its drawbacks. For example, 
it leaves catheter needle scars and can cause pain, de-
pending on the angle of the catheter needle.5-6 It was 
expected that, if a patient is young, having catheter 
needle scars left would lead to a negative body image. In 
addition, since young patients are more active and move 
around significantly, the angle of the catheter needle is 
liable to change, causing pain. These are assumed to 
have been the reasons for the significant differences at-
tributable to age.
 No significant differences were seen in other items. 
However, in terms of treatment history, only those whose 
history of treatment was 10–20 years had more partici-
pants who were “dissatisfied” than “satisfied,” showing 
an opposite trend. Approximately 80% of patients with a 
treatment history spanning 10–20 years were likely to be 
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female and in their 30s to 40s. In Japan, patients in this 
age group are reported to significantly prioritize doing 
housework for their family or working to earn a living 
over taking care of their diabetes so their blood sugar 
control tends to be erratic.7 Our study appears to show 
a similar pattern because of the same structure as that 
in the above report. Female patients appear to be work-
ing as co-breadwinners while raising children so as to 
be able to earn a satisfactory income to sustain a living. 
In Japan, generally treatment of type 1 diabetes tends to 
switch to CSII therapy in the case of poor blood glucose 
control by MDI therapy. Even after switching to CSII 
therapy, therefore, their blood sugar control failed to im-
prove sufficiently, which may explain the large number 
of participants who answered that they were “dissatis-
fied.”
Relationship between the degree of satisfaction 
with CSII therapy and views on diabetes treatment
A majority number of patients replied “yes, I have been 
dissatisfied” when asked if they agreed with the state-
ment “I have never been dissatisfied with the way my 
doctor dealt with me.” In a preceding study, 60% of the 
patients reportedly did not consult with their physicians 
in spite of harboring anxieties about treatment using 
insulin. Conversely, patients who had received full ex-
planations from their physicians were reported to have 
a high degree of satisfaction with their treatment using 
insulin.8Likewise, in our study, many patients who felt 
they received insufficient responses to their questions or 
explanations from physicians were believed to have an-
swered “yes, I have been dissatisfied.” To the item “pay-
ment for medical treatments imposes a heavy financial 
burden,” however, a large number of patients answered 
“yes” despite their being either satisfied or dissatisfied. 
Regarding financial burden, it has already been suggest-
ed that the worse a patient’s diabetes becomes and the 
more advanced its complications, the higher the treat-
ment fees become which adversely affects the degree of 
satisfaction with treatment, thus causing a reduction in 
QOL.9 Our study also showed that many patients were 
suffering from the burden of medical payments. Even 
though their burden of medical payments may be very 
heavy, some patients answered that they were “satis-
fied” with their treatment while others answered that 
they were “dissatisfied.” One item of information that 
became clear in our study was that “payment for medi-
cal treatments imposes a heavy financial burden” was 
not necessarily directly linked to degree of satisfaction 
with the treatment. Going forward, therefore, studies of 
assistance and support are required that are tailored to 
the patients’ psychological and social conditions while 
undergoing CSII therapy.
Patients’ evaluation of CSII therapy
Judging by the basic attributes of our study participants, 
many patients appear to have switched from MDI thera-
py to CSII therapy. Having changed to CSII therapy, the 
patients commented that their blood sugar and HbAlc 
levels had dropped, they suffered fewer instances of 
hypoglycemia, and they acknowledged an improvement 
in their health. As examples of positive evaluations, 
they cited two things: their “gratitude for CSII therapy,” 
which released them from the hassle of blood sugar 
control and the pain of seeing hypoglycemia develop, 
and gaining a sense of mental stability; and “hopes for 
CSII therapy,” i.e., that this therapy would become more 
widespread and benefit a greater number of type 1 dia-
betes patients. CSII therapy has been proven useful in 
that it enables the maintenance of blood sugar control 
using smaller doses of insulin than MDI therapy and that 
it is less liable to induce hypoglycemia.6 Likewise, the 
results of our study suggest that a reduction in the bur-
den of having to adjust their insulin dose by themselves, 
the improvement in blood sugar and HbA1c levels, and 
a reduction in the incidence of hypoglycemia have led 
to favorable evaluations. Regardless of the participants’ 
thoughts about CSII therapy, however, they showed a 
desire to “draw a distinction between type 2 and type 
1 diabetes,” or, in other words, to clarify the difference 
from type 2 diabetes, a disease that develops because of 
lifestyle habits and aging. These patients are believed to 
be receiving CSII therapy while facing the psychological 
stress of getting their disease mixed up with type 2 dia-
betes. In addition to this psychological stress, CSII thera-
py has a number of drawbacks. First, it imposes a unique 
burden on the body; since the site of needle insertion is 
limited to the abdomen and since insulin is consistently 
injected via an indwelling needle, the procedure causes 
itchiness and hardening of the skin. Second, it entails 
the burden of having to visit a hospital every month; 
even with CSII therapy, patients must be examined 
monthly so the interval between hospital visits is short. 
Third, it creates a sense of financial difficulty because of 
medical payments; patients must take a leave of absence 
from work when receiving outpatient treatment and are 
burdened with increased medical costs. As revealed in 
this study, patients experience adverse physical effects 
that are unique to CSII therapy and experience a feeling 
of difficulties that are directly linked to a public life.
 Another noteworthy finding was that the participants 
adversely evaluated items relating to medical treatment 
and social security setups for type 1 diabetes patients, 
such as “distrust of high-cost medical treatments,” “dis-
trust of healthcare providers,” and “financial anxieties 
toward the future.” In Japan, patients with type 1 diabe-
tes are eligible to receive public medical assistance up to 
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age 18 based on the government’s program of medical 
benefits for specific childhood chronic diseases. After 
they pass the age of 18, however, they are no longer eli-
gible and lose medical assistance. Moreover, CSII thera-
py earns greater medical remuneration points than MDI 
therapy, adding to the patients’ financial burden. The 
current situation of healthcare providers giving insuffi-
cient explanation about the treatment, including medical 
costs, and not providing sufficient information overall, 
is likely to result in distrust on the part of the patients 
of high-cost medical treatment as well as of healthcare 
providers, adding to the distress that the patients are al-
ready suffering. As a result, anxieties on the part of the 
patients become more pronounced, leading to worries 
about future financial insecurity. If a person develops 
type 1 diabetes, a system of public medical subsidies is 
available at least during childhood; a support network 
has also been established through summer camps for pe-
diatric diabetes patients. After adulthood, however, the 
support network becomes insufficient with no system in 
place to help solve problems that occur. Medical treat-
ment is not made clearly visible.10 The same can also 
be said to be found in our study. Type 1 diabetes is not 
the only disease where the burden of medical payments 
results in financial anxieties on the part of patients. In-
dividuals with chronic illnesses, such as type 2 diabetes 
patients who are undergoing insulin therapy and cancer 
patients who receive chemotherapy, are reported to 
experience financial anxieties when undergoing treat-
ment. Type 1 diabetes patients, however, must continue 
to inject insulin every day before each meal for the rest 
of their lives, making their burden of medical payments 
especially serious. In our study, the patients stated their 
“hopes for medical advancements,” expressing their des-
perate wish that low-cost insulin preparations and sim-
pler medical and measurement devices will be developed 
and approved as soon as possible, and that revolutionary 
treatment that is both effective and less burdensome to 
them will become available.
 When comparing the results of a survey on the de-
gree of satisfaction with treatment and the participants’ 
unstructured comments, we found that, in the survey, 
more participants answered that they were “satisfied” 
than “dissatisfied.” However, many wrote in the unstruc-
tured comment space that they were “dissatisfied” with 
CSII therapy. CSII therapy makes it possible to maintain 
blood sugar control over a long period of time, which is 
a huge advantage for the patients. However, it also has a 
significant disadvantage in terms of cost. This is likely to 
have been why we observed such mixed feelings. It has 
been reported, moreover, that the respondents of Internet 
surveys are not reluctant to say what they honestly feel, 
since this type of survey cannot identify the anonymous 
respondents.11 Indeed, because this was an Internet sur-
vey, the participants are believed to have revealed their 
honest and unfiltered opinions without hesitation in the 
unstructured comments space concerning their dissatis-
factions with their treatment.
Proposals for nursing care 
The greatest number of comments we heard from the 
patients in this study pertained to the high cost of CSII 
therapy. As future countermeasures, we believe sup-
port will be necessary to assist the patients to continue 
undergoing this therapy with peace of mind. This might 
include enhancing patient education, including the pro-
vision of information on medical expenses, encouraging 
exchanges between patients, and setting up a contact 
point where they feel they are welcome to ask for con-
sultations. Although few, we also heard several patients 
express their distrust of medical personnel. As a mea-
sure to counter this, it is important for nurses to actively 
communicate with the patients and provide assistance 
after understanding what patients see as problematic 
and burdensome about CSII therapy.
Acknowledgments: We thank all patients with type 1 diabetes 
who participated in this study. We would like to thank Eli Lilly 
Japan K.K., for performing data collection.
The authors declare no conflict of interest. 
REFERENCES
  1 Lorig K, Holman H, Sobel D, Laurent D, González V, 
Minor M. Living a healthy life with chronic conditions: self-
management of heart disease, fatigue, arthritis, worry, diabe-
tes, frustration, asthma, pain, emphysema, and others. 3rd ed. 
Chicago: American Lung Association; 2013. p. 317-39.
  2 Didangelos T, Iliadis F. Insulin pump therapy in adults. Dia-
betes Research and Clinical Practice. 2011;93:109-13. PMID: 
21864741. 
  3 Pickup JC. Insulin-pump therapy for type 1 diabetes melitus. 
N Engl J Med. 2012;366:1616-24. PMID: 22533577.
  4 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, 
Motoyoshi S. Intensive insulin therapy prevents the progres-
sion of diabetic microvascular complications in Japanese 
patients with non-insulin-dependent diabetes mellitus: a 
randomized prospective 6-year study. Diabetes Research and 
Clinical Practice. 1995;28:103-17. PMID: 7587918. 
  5 Shetty G, Wolpert H. Insulin pump use in adults with type 1 
diabetes–practical issue. Diabetes Technol Ther. 2010;12:11-6. 
PMID: 20515299.
  6 Saarinen T, Fernström L, Brorsson A.-L, Olinder A.L. Insulin 
pump therapy is perceived as liberating, but to many it can 
imply a sense of the diabetes made visible. European Diabetes 
Nursing. 2014;11:38-42. DOI: 10.1002/edn.246. 
  7 Kawaguchi T. Nursing and QOL of patients with diabetes. 
107
Satisfaction with CSII therapy in T1D patients
Tokyo: Igaku Shoin; 2000. p. 136-45. Japanese.
  8 Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, 
et al. Assessing psychosocial distress in diabetes: development 
of the diabetes distress scale. Diabetes Care. 2005;28:626-31. 
PMID: 15735199. 
  9 Gordois A, Oglesby A, Scuffham P, Tobian JA, Shearer A. 
The health care costs of diabetic peripheral neuropathy in the 
U.S. Diabetes Care. 2003;26:1790-5. PMID: 12766111. 
10 Lundin CS, O¨ hrn I, Danielson E. From multidimensional 
support to decreasing visibility: A field study on care culture 
in paediatric and adult diabetes outpatient clinics. Int J Nurs 
Stud. 2008;45:180-90. PMID: 16979642.
11 Dillman DA. Mail and internet surveys: the tailored design 
method. New York: John Wiley; 2000. p. 352-73.
